Eurofins Viracor launches Epstein-Barr Virus (EBV) inSIGHT™ to Evaluate T Cell Mediated Immunity to Epstein-Barr Virus
LENEXA, Kan., Oct. 3, 2022 /PRNewswire/ — Eurofins Viracor, a leader in infectious disease and immunology testing, launches EBV inSIGHT™, a functional T Cell test to measure CD4 and CD8 Epstein-Barr virus-specific T cell immune response. The test joins the innovative inSIGHT diagnostic portfolio of virus-specific cell mediated immunity tests offered by Viracor.
EBV is a common risk factor for post-transplant lymphoproliferative disorders (PTLD) in patients following solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). PTLD can arise due to immunosuppression and the loss of T cells that typically control EBV reactivation.
The test targets EBV cell lysate, BZLF1 (lytic phase), and EBNA3 (latent phase) antigens; reporting Interferon-γ (IFN-gamma), as well as polyfunctional CD4 and CD8 T cells. The presence of virus specific polyfunctional T cells has been found to be an indicator of highly functional T cell response. Research has shown patients with PTLD have shown impaired function and a low proportion of polyfunctional T Cells.1 Additionally, in the case of EBV induced PTLD, research has also found that highly functional EBV Specific CD8 T Cells are required to control an infection.2
Quantitative EBV DNA PCR can also be used to monitor the course of the disease, aid in the early diagnosis of PTLD, and monitor response to treatment.
To learn more, please visit: https://www.eurofins-viracor.com/clinical/test-menu/33217-ebv-insight-t-cell-immunity/
Lam JKP, Hui KF, Ning RJ, Xu XQ, Chan KH and Chiang AKS (2018) Emergence of CD4+ and CD8+ Polyfunctional T Cell Responses Against Immunodominant Lytic and Latent EBV Antigens in Children With Primary EBV Infection. Front. Microbiol. 9:416. doi: 10.3389/fmicb.2018.00416Immunodominant 2018.00416
Ning, R. J., Xu, X. Q., Chan, K. H., & Chiang, A. K. (2011). Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunoNing, immunodominance hierarchies of EBV proteins. Immunology, 134(2), 161–171. https://doi.org/10.1111/j.1365-2567.2011.03476.
Eurofins Viracor has over 30 years of diagnostic expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients. Eurofins Viracor is a subsidiary of Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit https://www.eurofins.com/ and https://www.eurofins-viracor.com/clinical
Eurofins is Testing for Life. With 61,000 staff across a network of 940 laboratories in 59 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View original content:https://www.prnewswire.com/news-releases/eurofins-viracor-launches-epstein-barr-virus-ebv-insight-to-evaluate-t-cell-mediated-immunity-to-epstein-barr-virus-301639307.html
SOURCE Eurofins Viracor LLC